Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04544410
Registration number
NCT04544410
Ethics application status
Date submitted
30/08/2020
Date registered
10/09/2020
Date last updated
24/01/2024
Titles & IDs
Public title
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia
Query!
Secondary ID [1]
0
0
CAHmelia 204
Query!
Secondary ID [2]
0
0
SPR001-204
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Congenital Adrenal Hyperplasia
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other endocrine disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tildacerfont/Placebo
Experimental: Tildacerfont Group - Tildacerfont administered daily via oral tablet for 24 weeks at dose level 1; followed by open label tildacerfont for 52 weeks
Placebo Comparator: Placebo - Placebo administered daily via oral tablet for 24 weeks; followed by open label tildacerfont for 52 weeks
Treatment: Drugs: Tildacerfont/Placebo
Tablet, administered daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of subjects who can reduce GC dose at Week 24
Query!
Assessment method [1]
0
0
Proportion of subjects with at least a 5 mg/day HCe reduction from baseline in GC dose and A4 =ULN at Week 24
Query!
Timepoint [1]
0
0
24 Weeks
Query!
Secondary outcome [1]
0
0
Percentage change in GC use in subjects with CAH
Query!
Assessment method [1]
0
0
Percent change from baseline in GC dose at week 24
Query!
Timepoint [1]
0
0
24 weeks
Query!
Secondary outcome [2]
0
0
Change in the median cumulative HCe dose in subjects with CAH
Query!
Assessment method [2]
0
0
Median total cumulative GC dose in HCe at Week 24
Query!
Timepoint [2]
0
0
24 Weeks
Query!
Secondary outcome [3]
0
0
Effectiveness in reducing cardiovascular risk in subjects with CAH
Query!
Assessment method [3]
0
0
Proportion of subjects with improvement in at least one cardiovascular risk factor at week 24
Query!
Timepoint [3]
0
0
24 Weeks
Query!
Secondary outcome [4]
0
0
Effectiveness in improving HOMA-IR in subjects with CAH
Query!
Assessment method [4]
0
0
Change from baseline in the HOMA-IR at Week 24
Query!
Timepoint [4]
0
0
24 Weeks
Query!
Secondary outcome [5]
0
0
Effect on body weight in subjects with CAH
Query!
Assessment method [5]
0
0
Percent change from baseline in body weight after 24 weeks of tildacerfont treatment
Query!
Timepoint [5]
0
0
24 weeks
Query!
Secondary outcome [6]
0
0
Effect on body weight in subjects with CAH
Query!
Assessment method [6]
0
0
Percent change from baseline in body weight after 52 weeks of tildacerfont treatment
Query!
Timepoint [6]
0
0
52 weeks
Query!
Eligibility
Key inclusion criteria
- Male and female subjects over 18 years old, inclusive
- Has a documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency
based on genetic mutation in CYP21A2 and/or documented elevated 17-OHP and currently
treatment with HC, HC acetate, prednisone, prednisolone, methylprednisolone (or a
combination of the aforementioned GCs)
- Has been on a stable, supraphysiologic dose of GC replacement for =1 month before
screening.
- For subjects with the salt-wasting form of CAH, subject has been on a stable dose of
mineralocorticoid replacement for =1 month before screening
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has a known or suspected diagnosis of any other known form of classic CAH (not due to
21-hydroxylase deficiency)
- Has a history that includes bilateral adrenalectomy or hypopituitarism
- Has a history of allergy or hypersensitivity to tildacerfont, any of its excipients,
or any other CRF1 receptor antagonist
- Shows clinical signs or symptoms of adrenal insufficiency
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/09/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/09/2029
Query!
Actual
Query!
Sample size
Target
90
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Spruce Study Site - Brisbane
Query!
Recruitment hospital [2]
0
0
Spruce Study Site - Camperdown
Query!
Recruitment hospital [3]
0
0
Spruce Study Site - Melbourne
Query!
Recruitment hospital [4]
0
0
Spruce Study Site - Sydney
Query!
Recruitment postcode(s) [1]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
- Camperdown
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Recruitment postcode(s) [4]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Rhode Island
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
South Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Curitiba
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
São Paulo
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
Estonia
Query!
State/province [18]
0
0
Tallinn
Query!
Country [19]
0
0
Estonia
Query!
State/province [19]
0
0
Tartu
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Munich
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
Roma
Query!
Country [22]
0
0
Korea, Republic of
Query!
State/province [22]
0
0
Seoul
Query!
Country [23]
0
0
Latvia
Query!
State/province [23]
0
0
Riga
Query!
Country [24]
0
0
Lithuania
Query!
State/province [24]
0
0
Kaunas
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Kraków
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Warsaw
Query!
Country [27]
0
0
Romania
Query!
State/province [27]
0
0
Bucharest
Query!
Country [28]
0
0
Romania
Query!
State/province [28]
0
0
Bucuresti
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
Barcelona
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Madrid
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Sevilla
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Tarragona
Query!
Country [33]
0
0
Sweden
Query!
State/province [33]
0
0
Stockholm
Query!
Country [34]
0
0
Turkey
Query!
State/province [34]
0
0
Istanbul
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Birmingham
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Spruce Biosciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid
dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up
to 240 weeks.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04544410
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ron Newfield, M.D
Query!
Address
0
0
Rady Children's Hospital-San Diego and Professor of clinical pediatrics at UC San Diego School of Medicine.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04544410
Download to PDF